Why the study?
Are circulating metabolites of mitochondrial dysfunction differentially elevated in HFpEF versus HFrEF?
Are circulating metabolites of mitochondrial dysfunction differentially elevated in HFpEF versus HFrEF?
Metabolomic profiling identifies circulating biomarkers of impaired fatty acid oxidation that are associated with heart failure across the ejection fraction spectrum.
Answers are grounded in this paper and cite their sources.
May inform future HF biomarker research; leaves open clinical utility pending prospective validation.
We identified novel circulating metabolites reflecting impaired or dysregulated fatty acid oxidation that are independently associated with HF and differentially elevated in HFpEF and HFrEF. These results elucidate a specific metabolic pathway in HF and suggest a shared metabolic mechanism in HF along the LVEF spectrum.
No takes yet. Share an insight, caveat, or question.
Hunter et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: